Advertisement
open access | |
logout
Medical Conferences
Conference Reports
Conference Proceedings
Specialties
Cardiology
Dermatology
Endocrinology
Gastroenterology
Haematology
Nephrology
Neurology
Oncology
Psychiatry
Pulmonology
Rheumatology
Urology
Multimedia
Podcast channel
Video channel
About
2024 Medicom Conference Planning
About Conference Proceedings
Webinar
Home
>
Haematology
>
EHA 2024
EHA 2024
European Hematology Association
13
–
16 June 2024 Madrid, Spain
Table of Contents
Colophon
Table of Contents
Featured articles
Letter from the Editor
Editor
Prof. Gert Ossenkoppele, Amsterdam UMC, the Netherlands
Meet the Expert: Prof. C. Ola Landgren discusses MRD as a key endpoint in haematological cancer trials
Expert
Prof. C. Ola Landgren, University of Miami, FL, USA
EHA 2024 Highlights Podcast
Presented By
Robert van den Heuvel, Medicom
Multiple Myeloma
Isa-VRd proves its value in newly diagnosed MM in the IMROZ trial
Presented By
Prof. Thierry Facon, University of Lille, France
PERSEUS: High MRD negativity rates with D-VRd and consolidation therapy and D-R maintenance in MM
Presented By
Prof. Pieter Sonneveld, Erasmus University Medical Center, the Netherlands
Post-intensification data confirm superiority of quadruple therapy in MM
Presented By
Prof. Marc Raab, University Hospital Heidelberg, Germany
Promising phase 1 results for novel CAR T-cell therapy in MM
Presented By
Dr Binod Dhakal, Medical College of Wisconsin, WI, USA
DREAMM 8: Belantamab mafodotin offers hope for patients with RRMM
Presented By
Prof. Meletious Dimopoulos, University of Athens, Greece
Leukaemia
PhALLCON: Third-generation TKI superior to first-generation TKI in Ph+ ALL
Presented By
Prof. Jose Maria Ribera, Josep Carreras Leukaemia Research Institute, Spain
APOLLO: ATRA plus ATO meets expectations in high-risk APL
Presented By
Prof. Uwe Platzbecker, Leipzig University Hospital, Germany
Excellent phase 3 results for asciminib in chronic myeloid leukaemia
Presented By
Prof. Andreas Hochhaus, Jena University Hospital, Germany
AUGMENT-101: Revumenib trial in KMT2Ar leukaemia stopped early for efficacy
Presented By
Dr Ibrahim Aldoss, City of Hope National Medical Center, CA, USA
FLAG-Ida plus venetoclax induces high MRD-negativity rates in AML
Presented By
Dr Wei-Ying Jen, MD Anderson Cancer Center, TX, USA
CD40/CD47 inhibitor shows promise in high-risk MDS and AML
Presented By
Prof. Amer Zeidan, Yale University, CT, USA
ENHANCE: Magrolimab does not ameliorate health outcomes in high-risk MDS
Presented By
Dr David Sallman, Moffitt Cancer Center, FL, USA
Can MRD-guided azacitidine treatment improve outcomes in AML and MDS?
Presented By
Dr Anne Sophie Kubasch, University of Leipzig, Germany
Can WGTS replace standard-of-care diagnostics in AML?
Presented By
Dr Anna Staffas, University of Gothenburg, Sweden
Non-malignant Haematology
ENERGIZE: Mitapivat meets primary efficacy endpoint in thalassaemia
Presented By
Prof. Ali Taher, American University of Beirut, Lebanon
Sovleplenib delivers durable responses and QoL improvements in primary ITP
Presented By
Prof. Renchi Yang, Chinese Academy of Medical Sciences, China
Avatrombopag successful in children with chronic ITP
Presented By
Dr Rachael Grace, Harvard Medical School, MA, USA
RUBY: Promising data for first AsCas12a gene-editing therapy in sickle cell disease
Presented By
Dr Rabi Hanna, Cleveland Clinic, OH, USA
Encouraging data for ELA026 to treat secondary haemophagocytic lymphohistiocytosis
Presented By
Dr Abhishek Maiti, MD Anderson Cancer Center, TX, USA
Myelofibrosis
Navitoclax plus ruxolitinib leads to spleen volume reductions in myelofibrosis
Presented By
Prof. Naveen Pemmaraju, MD Anderson Cancer Center, TX, USA
Is pelabresib plus ruxolitinib the paradigm-shifting combo therapy for myelofibrosis?
Presented By
Dr Raajit Rampal, Memorial Sloan Kettering Cancer Center, NY, USA
Lymphoma
The landscape of TP53 mutations and their prognostic impact in CLL
Presented By
Dr Consuelo Bertossi, University Hospital Ulm, Germany
Can golcadomide plus R-CHOP become the first-line standard of care in high-risk BCL?
Presented By
Dr Marc Hoffman, The University of Kansas Cancer Center, KS, USA
High survival rates following atezolizumab consolidation in DLBCL
Presented By
Dr Marcel Nijland, University Medical Center Groningen, the Netherlands
First results for zanubrutinib plus venetoclax in del(17p)/TP53-mutated CLL/SLL
Presented By
Prof. Paolo Ghia, University Vita-Salute San Raffaele, Italy
EPCORE CLL-1: Promising data for epcoritamab in high-risk Richter’s transformation
Presented By
Prof. Arnon Kater, University of Amsterdam, the Netherlands
Updates from the EBMT Lymphoma Working Group: outcomes after allo- and auto-SCT for T-cell lymphoma subtypes
Presented By
Dr Evgenii Shumilov, University of Münster, Germany
ECHO: Can we expect a novel standard of care in newly diagnosed MCL?
Presented By
Prof. Michael Wang, University of Texas, TX, USA
Clinically meaningful outcomes for mosunetuzumab across follicular lymphoma subgroups
Presented By
Dr Sarit Assouline, Jewish General Hospital, Canada